Myriad Genetics (MYGN) Receivables (2010 - 2026)

Myriad Genetics has disclosed Receivables across 17 years of filings, most recently posting $123.8 million for Q1 2026.

• In Q1 2026, Receivables rose 2.82% year-over-year to $123.8 million; the TTM figure through Mar 2026 stood at $123.8 million (up 2.82% YoY), while the FY2025 annual figure was $115.3 million, down 4.87% from the prior year.
• Receivables grew to $123.8 million in Q1 2026, from $115.3 million in the prior quarter.
• Over the last five years, Receivables for MYGN reached as high as $137.0 million in Q2 2025 and fell as low as $101.6 million in Q4 2022.
• The 5-year median for Receivables is $117.8 million (2024), against an average of $116.1 million.
• Annual changes were most pronounced in 2023 — Receivables gained 17.11% — and 2025, when it slipped 6.13%.
• A 5-year view of Receivables shows it stood at $101.6 million in 2022, then grew by 12.5% to $114.3 million in 2023, then gained by 6.04% to $121.2 million in 2024, then decreased by 4.87% to $115.3 million in 2025, then climbed by 7.37% to $123.8 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $123.8 million, $115.3 million, and $118.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.